Although PD-L1 exerts immunosuppressive effects through its interaction with PD-1 and ICOS promotes immune responses by enhancing T-cell activity, they may exhibit crossover or synergistic effects under specific conditions, such as cancer immune escape and immune checkpoint blockade therapy. This evidence concerns the gene PDCD1 and cancer.